|
| related topics |
| {product, candidate, development} |
| {product, liability, claim} |
| {regulation, government, change} |
| {system, service, information} |
| {financial, litigation, operation} |
| {acquisition, growth, future} |
| {operation, international, foreign} |
| {loan, real, estate} |
|
|
The Company faces competition from other pharmaceutical manufacturers, including from lower-priced generic products, and it is possible that the Company may lose market exclusivity of a product earlier than expected.
The patent infringement lawsuit with Apotex Inc. and Apotex Corp. (Apotex) involving PLAVIX* is ongoing, and there is a risk of generic competition from Apotex and from other generic pharmaceutical companies.
The Company may be adversely impacted by economic factors beyond its control and may incur additional impairment charges to its investment portfolio.
The Company may experience difficulties and delays in the manufacturing and sale of its products.
The Company may experience difficulties or delays in the development and commercialization of new products.
There are legal matters in which adverse outcomes could negatively affect the Company s business.
U.S. and foreign regulations may negatively affect the Company s sales and profit margins.
The Company faces increased pricing pressure in the U.S. and abroad from managed care organizations, institutional purchasers, and government agencies and programs that could negatively affect the Company s sales and profit margins.
The Company relies on third parties to meet their contractual, regulatory, and other obligations.
Failure to execute the Company s business strategy could adversely impact its growth and profitability.
The Company is increasingly dependent on its information technology and outsourcing arrangements.
Full 10-K form ▸
|
|
| related documents |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 14272--2/20/2009--BRISTOL_MYERS_SQUIBB_CO |
| 914475--2/7/2006--NEUROCRINE_BIOSCIENCES_INC |
| 858803--12/17/2008--AVANIR_PHARMACEUTICALS |
| 858803--12/21/2007--AVANIR_PHARMACEUTICALS |
| 38074--5/30/2008--FOREST_LABORATORIES_INC |
| 38074--5/30/2007--FOREST_LABORATORIES_INC |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 1000694--3/6/2006--NOVAVAX_INC |
| 897075--3/17/2008--REPROS_THERAPEUTICS_INC. |
| 1123361--3/6/2007--VIASYS_HEALTHCARE_INC |
| 1123361--3/14/2006--VIASYS_HEALTHCARE_INC |
| 1020214--2/26/2007--CERUS_CORP |
| 810509--3/31/2008--NEOPROBE_CORP |
| 943736--3/31/2006--MED-DESIGN_CORP |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 897075--3/16/2009--REPROS_THERAPEUTICS_INC. |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 310158--2/28/2006--SCHERING_PLOUGH_CORP |
| 849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 71478--3/15/2006--LIPID_SCIENCES_INC/ |
| 816284--2/17/2009--CELGENE_CORP_/DE/ |
| 1041859--4/12/2006--CHILDRENS_PLACE_RETAIL_STORES_INC |
| 1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC |
| 874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA |
| 23259--3/31/2006--CT_COMMUNICATIONS_INC_/NC |
| 1020214--3/11/2010--CERUS_CORP |
|